---
title: "alectinib"
slug: "alectinib"
date: "2023-11-06"
enableToc: false
tags:
  - building
---

# alectinib

- Non-small Cell Lung Cancer (NSCLC)
- Treatment of ALK-positive stage IV NSCLC (designated an orphan drug by FDA for this use).
- Guidelines for the treatment of stage IV NSCLC in patients with driver alterations in ALK generally support use of alectinib as an option in the first-line setting and in the second-line setting following therapy with crizotinib.
- Confirmation of ALK rearrangement necessary prior to initiation of therapy.

### Backlink

- [[non-small cell lung cancers]]
- [[NSCLC]]
- [[Adeno or Other in Stage IV NSCLC Treatment]]
- [[ALK]]
